Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2016

View Archived Issues

Renaissance topical division sold to Mylan

Kyushu University and Nippon Chemiphar begin phase I trial for NC-2600

MTD for PQR-309 determined in patients with advanced solid tumors

Phase II results for TRC-105 plus bevacizumab in patients with bevacizumab-refractory glioblastoma

Phase II results for CDX-1401 in patients with malignant melanoma pretreated with CDX-301

Boehringer Ingelheim discloses aldosterone synthase inhibitors

The Meghan Rose Bradley Foundation supports VBI Vaccines' immunotherapy research

Delta-Fly Pharma patents drug conjugates to treat cancer

C&C Research Laboratories announces STAT3 inhibitors

Actelion Pharmaceuticals divulges chemokine receptor agonists

Cerus enters into agreement with BARDA for INTERCEPT funding

Grunenthal reports TRPV1 ligands

The Medicines Co. presents new beta-lactamase inhibitors

Poxel advances phase I trial of direct AMPK activator PXL-770

Orbus Therapeutics' brain cancer drug receives EMA orphan medicinal product status

GSK's FULFIL study of closed triple combination therapy for COPD meets co-primary endpoints

TiGenix reports phase I/II results on AlloCSC-01

Orphazyme begins dosing patients in phase III AIDNPC interventional study

Circassia's phase III cat allergy study fails to meet primary endpoint

Japan Tobacco receives Japanese manufacturing and marketing approval for Genvoya

ARIAD Pharmaceuticals begins rolling NDA submission for brigatinib

Safety and pharmacokinetics of anti-IL-17 MAb assessed in phase I study

Phase II expansion investigates savolitinib with osimertinib for advanced EGFR-mutant NSCLC

MEDI-3902 combined with tobramycin shows promise in an acute pneumonia model

Summit Therapeutics enrolls first patient in Phaseout DMD study

FDA grants EUA to Hologic's Aptima Zika Virus assay

Roche's LightMix Modular Zika Virus Assay now available

Blade Therapeutics closes series B financing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...